Visual Abstract

Visual Abstract
Visual Abstract
View largeDownload slide
Keywords:
Autosomal dominant polycystic kidney disease, Tolvaptan , Vasopressin receptor 2 antagonist, Disease progression, Patient selection

Background: Tolvaptan can slow down renal function decline in autosomal dominant polycystic kidney disease (-ADPKD). While there is consensus across international recommendations that the drug should only be used in patients with high risk of rapid progression, identification criteria for rapid progression vary. Here, we investigated different assessment strategies using a real-life ADPKD cohort. Methods: Observational retrospective cohort analysis. The study included 131 ADPKD patients aged 19–78 years who were referred to the Hannover Medical School outpatient clinic for evaluation of tolvaptan treatment. Six different assessment strategies for tolvaptan eligibility were tested for each patient. Comparative analysis for different assessments was performed in the total study population, the subpopulation with available computed tomography/magnetic resonance imaging data, and the genotyped subpopulation. Results: Comparing 6 assessment strategies revealed strong variations in the individual selection processes resulting in treatment recommendations for 14.5–64.9% of patients. The highest patient number was selected by the Scottish and the lowest by the Japanese approach. Few patients had positive recommendations by all 6 systems, but strong congruency was observed between the Scottish, U.K. and Canadian patient selection. The lowest number of overlapping patients was found between the Japanese and the ERA-EDTA selection. Important discrepancies were also found between the ERA-EDTA and the U.S. system due to different emphases on parameters of kidney function versus kidney volume. Limitations of the study included the restricted sample size, heterogeneity in parameter availability and lack of outcome data. Conclusions: The study draws attention to important discrepancies between different decision algorithms for tolvaptan eligibility in ADPKD patients.

Keywords:
Autosomal dominant polycystic kidney disease, Tolvaptan , Vasopressin receptor 2 antagonist, Disease progression, Patient selection
1.
Ingelfinger JR. Tolvaptan and Autosomal Dominant Polycystic Kidney Disease.
N Engl J Med
. 2017 Nov;377(20):1988–9.
2.
Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, et al.; TEMPO 3:4 Trial Investigators. Tolvaptan in patients with autosomal dominant polycystic kidney disease.
N Engl J Med
. 2012 Dec;367(25):2407–18.
3.
Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Perrone RD, Koch G, et al.; REPRISE Trial Investigators. Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease.
N Engl J Med
. 2017 Nov;377(20):1930–42.
4.
Sans-Atxer L, Joly D. Tolvaptan in the treatment of autosomal dominant polycystic kidney disease: patient selection and special considerations.
Int J Nephrol Renovasc Dis
. 2018 Jan;11:41–51.
5.
Gansevoort RT, Arici M, Benzing T, Birn H, Capasso G, Covic A, et al. Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA Working Groups on Inherited Kidney Disorders and European Renal Best Practice.
Nephrol Dial Transplant
. 2016 Mar;31(3):337–48.
6.
Chebib FT, Perrone RD, Chapman AB, Dahl NK, Harris PC, Mrug M, et al. A Practical Guide for Treatment of Rapidly Progressive ADPKD with Tolvaptan.
J Am Soc Nephrol
. 2018 Oct;29(10):2458–70.
7.
Horie S, Mochizuki T, Muto S, Hanaoka K, Fukushima Y, Narita I, et al. Evidence-based clinical practice guidelines for polycystic kidney disease 2014.
Clin Exp Nephrol
. 2016 Aug;20(4):493–509.
8.
Soroka S, Alam A, Bevilacqua M, Girard LP, Komenda P, Loertscher R, et al. Updated Canadian Expert Consensus on Assessing Risk of Disease Progression and Pharmacological Management of Autosomal Dominant Polycystic Kidney Disease.
Can J Kidney Health Dis
. 2018 Oct;5:2054358118801589.
9.
Ong AC, Ashley C, Harris T, et al. Commentary on the NICE Guideline on Tolvaptan for treating autosomal dominant polycystic kidney disease (accessed: November 30, 2018). Available from: https://renal.org/wp-content/uploads/2017/06/tolvaptan-in-adpkd-nice-commentary.pdf.
10.
Renal Unit of the Royal Infirmary of Edinburgh. PKD and use of Tolvaptan (accessed: November 27, 2018). Available from: http://www.edren.org/pages/handbooks/unit-handbook/pkd.php.
11.
Torres VE. Pro: tolvaptan delays the progression of autosomal dominant polycystic kidney disease.
Nephrol Dial Transplant
. 2019 Jan 1;34(1):30–4.
12.
Mayo Foundation and Medical Education and Research. Classification of typical ADPKD calculator (accessed: October, 2018). Available from: https://www.mayo.edu/research/documents/pkd-center-adpkd-classification/doc-20094754.
13.
Renal Unit of the Royal Infirmary of Edinburgh. Kidney volume calculator for PKD (accessed: October, 2018). Available from: https://jscalc.io/calc/EbgTWdRdVXaqRoEk.
14.
Cornec-Le Gall E, Audrézet MP, Rousseau A, Hourmant M, Renaudineau E, Charasse C, et al. The PROPKD Score: A New Algorithm to Predict Renal Survival in Autosomal Dominant Polycystic Kidney Disease.
J Am Soc Nephrol
. 2016 Mar;27(3):942–51.
15.
Ong AC, Devuyst O, Knebelmann B, Walz G; ERA-EDTA Working Group for Inherited Kidney Diseases. Autosomal dominant polycystic kidney disease: the changing face of clinical management.
Lancet
. 2015 May;385(9981):1993–2002.
16.
Cornec-Le Gall E, Chebib FT, Madsen CD, Senum SR, Heyer CM, Lanpher BC, et al.; HALT Progression of Polycystic Kidney Disease Group Investigators. The Value of Genetic Testing in Polycystic Kidney Diseases Illustrated by a Family With PKD2 and COL4A1 Mutations.
Am J Kidney Dis
. 2018 Aug;72(2):302–8.
17.
Harris T, Sandford R, de Coninck B, Devuyst O, Drenth JP, Ecder T, et al.; EAF co-chairs; EAF members; Roundtable participants. European ADPKD Forum multidisciplinary position statement on autosomal dominant polycystic kidney disease care: European ADPKD Forum and Multispecialist Roundtable participants.
Nephrol Dial Transplant
. 2018 Apr;33(4):563–73.
© 2019 S. Karger AG, Basel
2019
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.